Form 4: AbCellera CEO Granted 2.1M Stock Options

AbCellera Biologics Inc.'s CEO, Carl L. G. Hansen, was granted 2,106,505 share options with an exercise price of $3.42, vesting over four years.

Summary

• Carl L. G. Hansen, Chief Executive Officer, Director, and 10% Owner of AbCellera Biologics Inc. (ABCL), was granted 2,106,505 share options.
• The transaction date for this grant was January 1, 2026.
• Each share option has an exercise price of $3.42.
• The options vest and become exercisable monthly in substantially equal installments over a four-year period.
• The first tranche of these options is scheduled to vest on January 1, 2027, contingent on Mr. Hansen's continuous service to the Issuer.
• The options have an expiration date of January 1, 2036.
• Following this transaction, Mr. Hansen beneficially owns 13,096,837 derivative securities.

Sentiment

Score: 7

Explanation: The grant of a significant number of stock options to the CEO is a standard executive compensation practice designed to align management's long-term interests with those of shareholders. It reflects ongoing commitment but does not directly indicate immediate operational performance.

Positives

• The grant of stock options to the CEO aligns management's long-term interests with those of shareholders, incentivizing sustained performance.
• The four-year vesting schedule encourages the CEO's continued service and commitment to the company's strategic objectives.

Future Outlook

The vesting schedule of the granted options over a four-year period suggests a long-term commitment from the Chief Executive Officer, aligning his incentives with the company's sustained growth and performance.

Industry Context

Executive stock option grants are a common and widely accepted form of compensation in the biotechnology and pharmaceutical industries. They are designed to attract, retain, and motivate key executives by linking their personal financial success to the long-term performance of the company's stock.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, aiming to incentivize long-term performance and align management interests with shareholder value.
• While specific grant sizes vary based on company size, executive role, and performance metrics, this type of equity award is standard across comparable companies in the sector.

Related Party Transactions

• Grant of 2,106,505 share options to Carl L. G. Hansen, the Chief Executive Officer, Director, and 10% Owner of AbCellera Biologics Inc., as part of executive compensation.

Stakeholder Impact

• Shareholders: The grant aims to align the CEO's financial incentives with long-term shareholder value creation, potentially leading to improved company performance.
• Employees: May signal stability in leadership and a long-term vision for the company.

Next Steps

• Carl L. G. Hansen's continued service to AbCellera Biologics Inc. is required for the options to vest.
• The options will vest monthly over a four-year period, with the first vesting tranche on January 1, 2027.
• Mr. Hansen may choose to exercise the vested options at the exercise price of $3.42 per share at any time before the expiration date of January 1, 2036.

Key Dates

Keywords

AbCellera Biologics, ABCL, Carl L. G. Hansen, stock options, CEO, insider transaction, equity compensation, Form 4